Global Biosimilar Insulin Market Size, Share, Trends and Forecast 2022-2030

Description

Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
Industry Insights

Due to the COVID-19 pandemic, the global Biosimilar Insulin market size is estimated to be worth US$ 2558 million in 2021 and is forecast to a readjusted size of US$ 6548.3 million by 2028 with a CAGR of 14.2% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Biosimilar Insulin market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Biosimilar Insulin landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent

This report focuses on Biosimilar Insulin volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Biosimilar Insulin market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and India, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the Biosimilar Insulin market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

Biosimilar Insulin Glargine

Biosimilar Insulin Lispro

Other

Segment by Distribution Channel

Hospital

Retail Pharmacy

Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Eli Lilly

Sanofi

Gan&Lee

Tonghua Dongbao

United Laboratory

Geropharm

Biocon

Wockhardt

TABLE OF CONTENT

1 Biosimilar Insulin Market Overview
1.1 Product Overview and Scope of Biosimilar Insulin

1.2 Biosimilar Insulin Segment by Type

1.2.1 Global Biosimilar Insulin Sales Growth Rate Comparison by Type (2022-2028)

1.2.2 Biosimilar Insulin Glargine

1.2.3 Biosimilar Insulin Lispro

1.2.4 Other

1.3 Biosimilar Insulin Segment by Distribution Channel

1.3.1 Global Biosimilar Insulin Sales Comparison by Distribution Channel: (2022-2028)

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Others

1.4 Global Biosimilar Insulin Market Size Estimates and Forecasts

1.4.1 Global Biosimilar Insulin Revenue 2017-2028

1.4.2 Global Biosimilar Insulin Sales 2017-2028

1.4.3 Biosimilar Insulin Market Size by Region: 2017 Versus 2021 Versus 2028

2 Biosimilar Insulin Market Competition by Manufacturers

2.1 Global Biosimilar Insulin Sales Market Share by Manufacturers (2017-2022)

2.2 Global Biosimilar Insulin Revenue Market Share by Manufacturers (2017-2022)

2.3 Global Biosimilar Insulin Average Price by Manufacturers (2017-2022)

2.4 Manufacturers Biosimilar Insulin Manufacturing Sites, Area Served, Product Type

2.5 Biosimilar Insulin Market Competitive Situation and Trends

2.5.1 Biosimilar Insulin Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest Biosimilar Insulin Players Market Share by Revenue

2.5.3 Global Biosimilar Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Biosimilar Insulin Retrospective Market Scenario by Region

3.1 Global Biosimilar Insulin Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global Biosimilar Insulin Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America Biosimilar Insulin Market Facts & Figures by Country

3.3.1 North America Biosimilar Insulin Sales by Country

3.3.2 North America Biosimilar Insulin Revenue by Country

3.3.3 United States

3.3.4 Canada

3.4 Europe Biosimilar Insulin Market Facts & Figures by Country

3.4.1 Europe Biosimilar Insulin Sales by Country

3.4.2 Europe Biosimilar Insulin Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific Biosimilar Insulin Market Facts & Figures by Region

3.5.1 Asia Pacific Biosimilar Insulin Sales by Region

3.5.2 Asia Pacific Biosimilar Insulin Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 China Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.6 Latin America Biosimilar Insulin Market Facts & Figures by Country

3.6.1 Latin America Biosimilar Insulin Sales by Country

3.6.2 Latin America Biosimilar Insulin Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.7 Middle East and Africa Biosimilar Insulin Market Facts & Figures by Country

3.7.1 Middle East and Africa Biosimilar Insulin Sales by Country

3.7.2 Middle East and Africa Biosimilar Insulin Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global Biosimilar Insulin Historic Market Analysis by Type

4.1 Global Biosimilar Insulin Sales Market Share by Type (2017-2022)

4.2 Global Biosimilar Insulin Revenue Market Share by Type (2017-2022)

4.3 Global Biosimilar Insulin Price by Type (2017-2022)

5 Global Biosimilar Insulin Historic Market Analysis by Distribution Channel

5.1 Global Biosimilar Insulin Sales Market Share by Distribution Channel (2017-2022)

5.2 Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2017-2022)

5.3 Global Biosimilar Insulin Price by Distribution Channel (2017-2022)

6 Key Companies Profiled

6.1 Eli Lilly

6.1.1 Eli Lilly Corporation Information

6.1.2 Eli Lilly Description and Business Overview

6.1.3 Eli Lilly Biosimilar Insulin Sales, Revenue and Gross Margin (2017-2022)

6.1.4 Eli Lilly Biosimilar Insulin Product Portfolio

6.1.5 Eli Lilly Recent Developments/Updates

6.2 Sanofi

6.2.1 Sanofi Corporation Information

6.2.2 Sanofi Description and Business Overview

6.2.3 Sanofi Biosimilar Insulin Sales, Revenue and Gross Margin (2017-2022)

6.2.4 Sanofi Biosimilar Insulin Product Portfolio

6.2.5 Sanofi Recent Developments/Updates

6.3 Gan&Lee

6.3.1 Gan&Lee Corporation Information

6.3.2 Gan&Lee Description and Business Overview

6.3.3 Gan&Lee Biosimilar Insulin Sales, Revenue and Gross Margin (2017-2022)

6.3.4 Gan&Lee Biosimilar Insulin Product Portfolio

6.3.5 Gan&Lee Recent Developments/Updates

6.4 Tonghua Dongbao

6.4.1 Tonghua Dongbao Corporation Information

6.4.2 Tonghua Dongbao Description and Business Overview

6.4.3 Tonghua Dongbao Biosimilar Insulin Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Tonghua Dongbao Biosimilar Insulin Product Portfolio

6.4.5 Tonghua Dongbao Recent Developments/Updates

6.5 United Laboratory

6.5.1 United Laboratory Corporation Information

6.5.2 United Laboratory Description and Business Overview

6.5.3 United Laboratory Biosimilar Insulin Sales, Revenue and Gross Margin (2017-2022)

6.5.4 United Laboratory Biosimilar Insulin Product Portfolio

6.5.5 United Laboratory Recent Developments/Updates

6.6 Geropharm

6.6.1 Geropharm Corporation Information

6.6.2 Geropharm Description and Business Overview

6.6.3 Geropharm Biosimilar Insulin Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Geropharm Biosimilar Insulin Product Portfolio

6.6.5 Geropharm Recent Developments/Updates

6.7 Biocon

6.6.1 Biocon Corporation Information

6.6.2 Biocon Description and Business Overview

6.6.3 Biocon Biosimilar Insulin Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Biocon Biosimilar Insulin Product Portfolio

6.7.5 Biocon Recent Developments/Updates

6.8 Wockhardt

6.8.1 Wockhardt Corporation Information

6.8.2 Wockhardt Description and Business Overview

6.8.3 Wockhardt Biosimilar Insulin Sales, Revenue and Gross Margin (2017-2022)

6.8.4 Wockhardt Biosimilar Insulin Product Portfolio

6.8.5 Wockhardt Recent Developments/Updates

7 Biosimilar Insulin Manufacturing Cost Analysis

7.1 Biosimilar Insulin Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of Biosimilar Insulin

7.4 Biosimilar Insulin Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 Biosimilar Insulin Distributors List

8.3 Biosimilar Insulin Customers

9 Biosimilar Insulin Market Dynamics

9.1 Biosimilar Insulin Industry Trends

9.2 Biosimilar Insulin Market Drivers

9.3 Biosimilar Insulin Market Challenges

9.4 Biosimilar Insulin Market Restraints

10 Global Market Forecast

10.1 Biosimilar Insulin Market Estimates and Projections by Type

10.1.1 Global Forecasted Sales of Biosimilar Insulin by Type (2023-2028)

10.1.2 Global Forecasted Revenue of Biosimilar Insulin by Type (2023-2028)

10.2 Biosimilar Insulin Market Estimates and Projections by Distribution Channel

10.2.1 Global Forecasted Sales of Biosimilar Insulin by Distribution Channel (2023-2028)

10.2.2 Global Forecasted Revenue of Biosimilar Insulin by Distribution Channel (2023-2028)

10.3 Biosimilar Insulin Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of Biosimilar Insulin by Region (2023-2028)

10.3.2 Global Forecasted Revenue of Biosimilar Insulin by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample